Pembrolizumab generated antitumor activity in patients with BCG-unresponsive, papillary high-risk non–muscle-invasive bladder cancer, according to cohort B of the phase 2 Keynote-057 trial.
Data presented from cohort B of the phase 2 Keynote-057 trial (NCT02625961) showed that pembrolizumab (Keytruda) elicited antitumor activity in patients with BCG-unresponsive, papillary high-risk non–muscle-invasive bladder cancer (NMIBC) after approximately 45 months of follow-up, according to findings presented at the 2023 American Society of Clinical Oncology Genitourinary Cancers Symposium.1
The phase 2 Keynote-057 trial (NCT02625961) evaluated the safety and efficacy of pembrolizumab monotherapy in patients with BCG-unresponsive high-risk NMIBC who were either ineligible for or declined to undergo radical cystectomy, according to a presentation from Andrea Necchi, MD, associate professor at Vita-Salute San Raffaele University and head of Genitourinary Medical Oncology at the San Raffaele Hospital in Milan, Italy.
Previously reported results from Cohort A of the trial, which evaluated the treatment in patients with carcinoma in situ (CIS) with or without papillary tumors, showed a clinical complete response rate of 40.6% at 3 months, along with a median duration of response of 16.2 months.2 This resulted in the FDA approving pembrolizumab for use in this patient population.
In his presentation, Necchi noted that although prior research has been conducted in patients with BCG-unresponsive CIS3, limited data exist regarding the use of novel systemic therapies in non-CIS, high-grade papillary T1 or Ta disease. Accordingly, cohort B of the Keynote-057 trial evaluated patients with papillary tumors only and no CIS.
Cohort B included patients who were at least 18 years of age with BCG-unresponsive high-risk NMIBC with papillary tumors only at baseline, with an ECOG performance status of 0-2. Participants received 200 mg pembrolizumab every 3 weeks for 35 or fewer cycles, or approximately 2 years. Twelve-month disease-free survival (DFS) served as the primary end point. Secondary efficacy end points included 12-month DFS of any disease; progression-free survival (PFS) to worsening of grade, stage, or death; PFS to muscle invasion, metastasis, or death; and overall survival (OS).
A total of 132 patients received pembrolizumab, 104 (78.8%) of whom were male. Median patient age was 72 years (range, 37-87). The median follow-up was 45.4 months (range, 14.9-77.1). Patients had received a median of 10 prior instillations of BCG (range, 6-33); tumor stage at entry was T1 in 57 patients (43%) and high-grade Ta in 75 patients (57%); and baseline high-risk NMIBC status was persistent in 35 patients (26%), recurrent in 79 patients (60%), and progressive in 18 patients (14%).
The 12-month DFS rate in high-risk NMIBC was 43.5% (95% CI, 34.9%-51.9%), and the median DFS was 7.7 months (95% CI, 5.5-13.6). The 12-month rate of any-disease DFS (defined as low-grade Ta, high-risk NMIBC, and progressive disease) was 41.7% (95% CI, 33.1%-50.0%), and the median was 6.0 months (95% CI, 4.3-12.0). The 12-month PFS rate to worsening of grade, stage, or death was 88.2% (95% CI, 80.0%-93.2%), with a median of 44.5 months (95% CI, 34.6-not available). The 12-month PFS rate to muscle invasion, metastasis, or death was 88.2% (95% CI, 79.4%-93.3%), with a median of 46.2 months (95% CI, 36.8-not available). The 12-month OS rate was 96.2% (95% CI, 91.1%-98.4%), and the median was not reached.
Regarding treatment-related adverse events (TEAEs), 97 patients (73.5%) experienced a TEAE. In addition, 19 (14.4%) experienced a grade 3 or 4 TEAE, 17 (12.9%) experienced a serious TEAE, and 14 (10.6%) discontinued treatment due to TEAE. There were no deaths from TEAEs.
“In conclusion, pembrolizumab monotherapy showed antitumor activity in terms of disease-free survival rate in patients with BCG-unresponsive papillary high-risk non–muscle invasive disease after almost 45 months of follow-up…These results are among the most robust data yet available for any novel systemic therapy in this patient population,” said Necchi.
Darolutamide Becomes Routine Doublet and Triplet Option in Hormone-Sensitive Prostate Cancer
May 6th 2024Darolutamide has been adopted routinely in clinical practice as a component of both doublet and triplet regimens for the treatment of patients with metastatic hormone-sensitive prostate cancer.
Read More
Responders to UGN-101 Have Positive RFS in Upper Tract Urothelial Cancer
May 5th 2024In patients at 15 centers who had upper tract urothelial cancer, those with no evidence of disease after UGN-101 induction had a 68% rate of 3-year recurrence-free survival, and this outcome did not differ based on tumor status, method of instillation, or treatment intent.
Read More
UGN-101 Shows Promise for Upper Tract Urothelial Cancer Durability
May 5th 2024Maintenance UGN-101 therapy demonstrated good durability of response in initial responders with low-grade upper tract urothelial cancer, as evidenced by a low rate of disease progression in a multicenter, longitudinal follow-up study.
Read More